Gefitinib Active Not Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01933347Third-line Treatment of Gefitinib in NSCLC Patients
NCT01610336A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
NCT03399669The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer